Table 1.
Subject characteristics
| Control | HCM | |
|---|---|---|
| n | 20 | 50 |
| Gender (m/f, n) | 14/6 | 38/12 |
| Age (years) | 46±13.0 | 49±13.5 |
| Body mass index (kg/m2) | 22.6±2.2 | 27.4±4.4*** |
| NYHA function class (I/II/III, n) | NA | 25/24/1 |
| Dyspnoea (%) | NA | 52% |
| Chest pain (%) | NA | 28% |
| Presyncope (%) | NA | 36% |
| Syncope (%) | NA | 12% |
| Family history of HCM (%) | NA | 24% |
| Resting heart beat (beats/min) | 62.8±8.7 | 60.5±10.5 |
| Systolic blood pressure (mmHg) | 120.4±10.2 | 128.3±12.5 |
| Diastolic blood pressure (mmHg) | 73.0±9.8 | 72.4±9.0 |
| eGFR (mL/min/1.75 m2) | 86.4±4.5 | 83.6±11.4 |
| Medications | ||
| β-blockers | NA | 54% |
| Calcium channel blockers | NA | 18% |
| Angiotensin convert enzyme inhibitor | NA | 12% |
| Angiotensin receptor blockers | NA | 10% |
| Statin | NA | 18% |
| Full blood count | ||
| Haemoglobin (g/L) | 144.6±9.4 | 146.5±14.3 |
| Platelets (109/L) | 227.3±53.8 | 208.3±56.1 |
| Hematocrit (L/L) | 0.42±0.03 | 0.42±0.04 |
| White blood cells (109/L) | 5.79±1.25 | 7.59±2.30** |
| Neutrophils (109/L) | 3.37±1.16 | 5.01±2.05** |
| Lymphocytes (109/L) | 1.89±0.54 | 1.89±0.53 |
| Monocytes (109/L) | 0.39±0.12 | 0.51±0.15** |
| Monocytes (%) | 6.83±1.84 | 6.90±1.78 |
Data are expressed as mean ± SD. HCM: Hypertrophic cardiomyopathy; NYHA: the New York Heart Association; eGFR: Estimated glomerular filtration rate.
**
P<0.01, vs. controls;
***
P<0.001, vs. controls.